In primary care, MDD can be reliably diagnosed and international treatment guidelines along with various algorithms are available to guide physicians in the treatment process. Major depressive disorder (MDD) is a common mental disorder that affects approximately 121 million people worldwide, and is among the leading causes of disability and disease burden. The recently approved prolonged-release formulation should provide further optimization of this antidepressant and may be useful for enabling an appropriate therapeutic dose to be administered with improved patient compliance. Trazodone is effective in controlling a wide range of symptoms of depression, while avoiding the negative effects on sleep seen with SSRI antidepressants. Overall, trazodone is an effective and well tolerated antidepressant (SARI) with an important role in the current treatment of MDD both as monotherapy and as part of a combination strategy. Other events reported, albeit with low incidence, include orthostatic hypotension (particularly in elderly patients or those with heart disease), minimal anticholinergic activity, corrected QT interval prolongation and torsade de pointes, cardiac arrhythmias, and rare occurrences of priapism and suicidal ideation. The most common adverse effects reported with trazodone are drowsiness (somnolence/sedation), headache, dizziness and dry mouth. Although trazodone is approved for the treatment of depression, evidence supports the use of low-dose trazodone as an off-label hypnotic for the treatment of sleep disorders in patients with MDD. Clinical studies have led to the recent approval in the USA of TzCOAD (as Oleptro™ Angelini Labopharm LLC, Princeton, NJ, USA), which may see resurgence of interest in the drug for the management of patients with MDD. Recent focus has been placed on the development of a new prolonged-release once-a-day formulation of trazodone (TzCOAD), which may provide improved tolerability over the conventional immediate-release formulation of trazodone. insomnia, anxiety and sexual dysfunction). Moreover, the SARI action of trazodone may overcome the tolerability issues that are often associated with second-generation antidepressants such as SSRIs (i.e. In clinical studies, trazodone has demonstrated comparable antidepressant activity to other drug classes, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and serotonin–noradrenaline (norepinephrine) reuptake inhibitors (SNRIs). The drug is approved and marketed in several countries worldwide for the treatment of major depressive disorder (MDD) in adult patients. The medication can also help in improving mood and feelings of well- being.Trazodone is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs). This belongs to the class of drugs called tricyclic antidepressants. It functions by increasing the amount of serotonin that helps preserve mental equilibrium, a natural product in the brain.Īmitriptyline is used for the treatment of depressions. Trazodone belongs to the medication called modulators of serotonin. Trazodone is used for the treatment of depression. The medication affects a certain chemical messenger which communicates between brain cells and helps in regulating mood. Trazodone is an oral antidepressant medicine that affects the brain's chemical messengers (neurotransmitters) that nerves use to interact with each other (stimulate).Īmitriptyline is a tricyclic antidepressant with sedative effects. And if you are doing well, continue taking trazodone. ![]() Before you experience the full benefit of trazodone, it can take 2 weeks or longer. Trazodone controls but does not heal, depression. Once your condition is regulated, your doctor can decrease your dosage. The doctor may start you on a low dose of trazodone and raise your dose gradually, not more often than once every three to four days. Swallow the extended-release tablets on the score mark, whole or split in half do not chew or crush them. Do not take more or less of this medication, take it more often, or take it longer than recommended by your doctor. Usually, the extended-release tablet is taken on an empty stomach once a day at bedtime, either one hour before or two hours after a meal. Two or three times a day, the tablet is normally taken with a meal or light snack. ![]() Trazodone comes as a tablet that can be taken by mouth and as an extended-release (long-lasting) tablet.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |